MONOPHARMA

Mono Pharmacare financials

Market cap
₹16 Cr
Sector
Healthcare

What Mono Pharmacare Ltd does

Mono Pharmacare Limited is a healthcare-sector company headquartered in Ahmedabad, Gujarat, listed on the NSE SME Emerge platform under the symbol MONOPHARMA. Its operations are closely tied to a group of related entities — including Supal Pharma, Supal Pharmacare Ltd, Supal Medical & Wholesale LLP, Ahmedabad Medical Corporation, Supal Distributors LLP and Supal Trading LLC-Dubai — with which it carries out sale/purchase transactions of goods in the ordinary course of business. The company holds a 99% stake in two associate entities, Ahmedabad Medical Corporation and Supal Distributors LLP, which operate in the same line of business. Its FY25 annual report records nil energy-conservation, technology-absorption and foreign-exchange activity, consistent with a trading/distribution rather than manufacturing operating model.

Associate/distribution entities
2 (99% stake each — Ahmedabad Medical Corporation, Supal Distributors LLP)
Geographic footprint
Domestic operations only — nil foreign exchange earnings/outgo in FY25
Founded 2022Headquarters Ahmedabad, Gujarat, India Company website

Quarterly results

Q4 FY26: revenue up 76.8%, net profit down 100.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ4 FY23Q2 FY24Q4 FY24Q2 FY25Q4 FY25Q2 FY26Q4 FY26
Revenue35 67 56 87 81 +131%66 −1%99 +77%
EBITDA2 4 2 5 3 +50%2 −50%2 +0%
Net profit1 2 1 2 1 +0%0 −100%0 −100%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −61.9% 1Y

₹10.0₹15.0₹20.0₹25.0Sept 25Oct 25Dec 25Jan 26Mar 26May 26Jun 26Aug 26

1Y: ₹23.5 on 10 Sept 2025 → ₹8.95. High ₹24.45 (15 Sept 2025), low ₹7.6 (10 Aug 2026).

Balance sheet

Year endingFY23FY24FY25
Equity capital₹12 Cr₹18 Cr₹18 Cr
Reserves₹1 Cr₹10 Cr₹14 Cr
Borrowings₹40 Cr₹41 Cr₹55 Cr
Other liabilities₹9 Cr₹12 Cr₹33 Cr
Total liabilities₹63 Cr₹81 Cr₹119 Cr
Fixed assets₹1 Cr₹1 Cr₹1 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr
Investments₹1 Cr₹0 Cr₹0 Cr
Other assets₹61 Cr₹80 Cr₹118 Cr
Total assets₹63 Cr₹81 Cr₹119 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Sep 2025

The ownership split has held steady since Sep 2024. The shareholder count grew 11% to 514.

Promoters
56.7%
Public
43.3%

Since Sep 2024

  • Promoters 0.00 pp
  • Public 0.00 pp

How it drifted, 6 quarters

Sep '23Mar '24Sep '25

Ownership split by quarter, oldest first. Sep '23: Promoters 56.7%, Public 43.3%.Dec '23: Promoters 56.7%, Public 43.3%.Mar '24: Promoters 56.7%, Public 43.3%.Sep '24: Promoters 56.7%, Public 43.3%.Mar '25: Promoters 56.7%, Public 43.3%.Sep '25: Promoters 56.7%, Public 43.3%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2025

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Sep 2025 filing

Every holder of Mono Pharmacare Ltd above SEBI's 1% disclosure line, and what changed since Mar 2025.

HolderStakeChange
Lakhatariya Panilam 45.43%unchanged
Supal Panilam Lakhatariya 11.28%unchanged
Harshad Rasiklal Sheth 3.68%unchanged
Thermo Capital Private Limited 2.33%+0.09 pp
L7 Hitech Private Limited 2.29%+0.98 pp
Prashil Sanjay Shah 1.79%unchanged
Yogeshkumar Rasiklal Sanghavi 1.63%+0.11 pp
Shah Amee T 1.28%unchanged
Manish Upendra Shanghvi 1.27%+0.19 pp
Bhawanji Keshavji Chheda 1.13%unchanged
Pallaviben Suhasbhai Shah 0.00%unchanged
Archit Shah 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.